Clearside Biomedical

Clearside Biomedical Debt Growth

Delisted

The Year-over-Year Debt Growth of Clearside Biomedical (CLSD) as of Nov 20, 2026 is -100.00 %. In the previous year, Year-over-Year Debt Growth was -80.78 % — a change of 23.80% (lower).

Debt Growth

-100.00 %

YoY

23.80%

Last updated:

Year-over-Year Debt Growth of Clearside Biomedical is 2021 -100.00 % . Year-over-Year Debt Growth of Clearside Biomedical was 2020 -80.78 % . It decreases by 23.80% lower compared to the previous year.

The Clearside Biomedical Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2016
26.92 USD
Jan 1, 2017
5.53 USD
Jan 1, 2018
24.59 USD
Jan 1, 2019
-48.40 USD
Jan 1, 2020
-80.78 USD
Jan 1, 2021
-100.00 USD
The Clearside Biomedical Debt Growth history
YEARDebt GrowthYoY
-100.00 %+23.80%
-80.78 %+66.91%
-48.40 %-296.78%
24.59 %+344.45%
5.53 %-79.45%
26.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Year-over-Year Debt Growth of Clearside Biomedical is -100.00 % in 2021.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Clearside Biomedical

All Key Metrics — Clearside Biomedical